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Purpose: Previous studies have demonstrated the prognostic impact of the prognostic nutritional index (PNI), a proposed 
indicator of immunonutritional statuses of surgical patients, on patients with various gastrointestinal cancers. Although 
the prognostic impact of the PNI on patients with colorectal cancer has been well established, its value has not been stud-
ied in patients treated with preoperative chemoradiation (pCRT). This study aimed to evaluate the prognostic impact of 
PNI on patients receiving pCRT for locally advanced rectal cancer (LARC).
Methods: Patients with LARC who underwent curative pCRT followed by surgical resection were enrolled. The PNI was 
measured in all patients before and after pCRT, and the difference in values was calculated as the PNI difference (dPNI). 
Patients were classified according to dPNI (<5, 5–10, and >10). Clinicopathologic parameters and long-term oncologic 
outcomes were assessed according to dPNI classification. 
Results: No significant intergroup differences were observed in clinicopathologic parameters such as age, histologic grade, 
tumor location, tumor-node-metastasis stage, and postoperative complications. Approximately 53% of the patients had a 
mild dPNI (<5); only 15% had a high dPNI (>10). Univariate and multivariate analyses identified the dPNI as an inde-
pendent prognostic factor for disease-free status (P < 0.01; hazard ratio [HR], 2.792; 95% confidence interval [CI], 1.577–
4.942) and for cancer-specific survival (P = 0.012; HR, 2.469; 95%CI, 1.225–4.978). 
Conclusion: The dPNI is predictive of long-term outcomes in pCRT-treated patients with LARC. Further prospective 
studies should investigate whether immune-nutritional status correction during pCRT would improve oncologic out-
comes.
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INTRODUCTION
In recent decades, many advances have been made in the treat-
ment of locally advanced rectal cancer (LARC), including multi-
disciplinary approaches involving surgery, radiotherapy, chemo-
therapy, and biologic agents. In particular, the combination of 
neoadjuvant chemoradiation therapy (CRT) and subsequent sur-
gery improves the likelihood of sphincter preservation, decreases 
the locoregional recurrence rate, and improves the long-term sur-
vival rate [1, 2]. 
Cancer patients frequently develop malnutrition, a significant 
risk factor with regard to treatment-related morbidity and mortal-
ity, as well as treatment failure [3-7]. Accordingly, attempts to ac-
curately evaluate and vigorously enhance the nutritional statuses 
of malnourished patients are ongoing [4, 7-9]. In particular, pa-
tients with LARC tend to have a worse nutritional status conse-
quent to a longer duration of illness and obstructive symptoms. 
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Furthermore, during neoadjuvant CRT, patients may develop ag-
gravated malnutrition subsequent to high-grade gastrointestinal 
(GI) toxicities induced by CRT. In this context, nutritional status 
evaluations to detect malnourished patients might be an impor-
tant step toward improving patient outcomes, and such monitor-
ing should be performed on a serial follow-up basis.
The prognostic nutritional index (PNI), which is based on the 
peripheral blood serum albumin level and total lymphocyte 
count, was first suggested as an indicator of the immunonutri-
tional statuses of surgical patients [10]. Notably, this index was 
found to correlate with postoperative morbidity and mortality. 
The efficiency, simplicity, and convenience of the PNI have led to 
its wide use as a tool for assessing the preoperative conditions and 
predicting the surgical risks of patients with GI malignancies. Re-
cent investigations have also revealed that the PNI reflects the im-
mune statuses of cancer patients and can serve as an independent 
prognostic factor for patients with various cancers [11-13]. 
Recent studies have shown that the preoperative PNI is a useful 
predictor of postoperative complications and survival in patients 
with colorectal cancer [14-17]. However, previous studies have 
addressed neither the efficiency of the PNI as a prognostic marker 
for patients with LARC nor changes in the immunonutritional 
statuses of patients during neoadjuvant CRT. Therefore, this study 
aimed to determine the relationship between the immunonutri-
tional status and prognoses in patients with LARC who were 
treated with neoadjuvant CRT followed by surgery, with a partic-
ular focus on changes in the immunonutritional status after pre-
operative chemoradiation (pCRT) and the impact of this parame-
ter on oncologic outcomes.
METHODS
Patients
A total of 341 patients with LARC who underwent preoperative 
CRT and subsequent surgery between January 2005 and Decem-
ber 2010 were identified from the Colorectal Cancer Registry of 
our institution, a prospective database. We retrospectively re-
viewed these patients’ medical records and excluded patients 
whose cases did not meet the following eligibility criteria: (1) ade-
nocarcinoma arising from the rectum, (2) completion of preoper-
ative CRT followed by surgery with curative intent, (3) American 
Joint Committee on Cancer (AJCC) stage 0 (complete pathologic 
response) to stage III, and (4) available follow-up data. The fol-
lowing additional exclusion criteria were applied: (1) distant me-
tastasis or surgery with palliative aim, (2) any palliative surgery 
(e.g., ileostomy) because of obstruction before preoperative CRT, 
and (3) missing clinical data because neoadjuvant CRT was ad-
ministered at other institutions or unclear laboratory results were 
recorded in the database. After these criteria had been applied, 80 
of the initial 341 patients were excluded (Fig. 1). This study was 
approved by the Institutional Review Board and informed con-
sent was waived. 
Clinicopathologic characteristics 
Patients’ clinicopathologic characteristics were collected retro-
spectively from medical records and evaluated as prognostic fac-
tors. Collected characteristics included age, sex, preoperative body 
mass index (BMI), histopathological tumor characteristics (dif-
ferentiation), distance from anal verge, TNM stage, comorbidity, 
postoperative complications, operation time, and use of adjuvant 
therapy. The 7th AJCC staging system was used to determine the 
TNM stages of the colorectal cancers. 
Postoperative complications were defined according to the Cla-
vien-Dindo classification [18]. Comorbidity was classified accord-
ing to the American Society of Anesthesiologists physical status 
classification system. Additionally, the following laboratory data 
were collected from peripheral blood analyses: carcinoembryonic 
antigen (CEA) and albumin levels, lymphocyte percentage, and 
lymphocyte count. The PNI was subsequently calculated using 
the following formula: 10 × serum albumin (g/dL) + 0.005 × total 
lymphocyte count (per mm3) [19]. The PNI values were deter-
mined at 2 points: before preoperative CRT (pre-CRT PNI), and 4 
weeks after the completion of preoperative CRT but before sur-
gery (post-CRT PNI). The PNI difference (dPNI) was calculated 
using the following formula: pre-CRT PNI – post-CRT PNI.
Preoperative chemoradiation and surgery
Indications for preoperative CRT included T3 or T4 disease or a 
positive lymph node status based on clinical and radiologic exam-
inations. Preoperative CRT comprised 5-fluorouracil (5-FU)-
based chemotherapy and pelvic irradiation (45–50 Gy in 25 frac-
tions over 5 weeks). Chemotherapy was administered as either a 
continuous intravenous infusion of 5-FU and leucovorin or oral 
capecitabine. Curative resection comprising total or partial meso-
rectal excision according to the tumor level was performed 6–8 
weeks after the completion of pCRT. Decisions regarding the per-
formance of a diverting loop ileostomy were made by the operat-
Fig. 1. Overall study design and overview of the patient population. 
CRT, chemoradiation therapy; CTx, chemotherapy; mets, metastasis. 
341 Patients diagnosed as having rectal cancer 
suregery after preoperative CRT ± Adjuvant CTx 
(2005.01.01−2010.12.31)
Exclusion criteria
33 Distant mets or palliative surpery
  6 Palliative stomy before CRT
41 Missing data
A total of 80 patients were excluded
261 Patients
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ing surgeon in consideration of the patient’s risk factors. Adjuvant 
chemotherapy was recommended for all patients within 4–6 
weeks after surgery. A pathologic examination, tumor regression 
grade (TRG) and standardized pathologic examination report 
were completed for every case. The standard form required man-
datory reporting of tumor differentiation, depth of tumor pene-
tration, lymph node metastasis, circumferential resection margin 
(CRM), lymphovascular invasion, and TRG, as suggested by 
Mandard et al. [20]. CRM involvement was defined as the pres-
ence of tumor cells from the outermost margin of the lesion to the 
proper mesorectal fascia or as a maximum distance of <1 mm be-
tween the tumor and proper rectal fascia. 
Follow-up policy
Patients underwent routine check-ups every 3 months for up to 2 
years and then every 6 months for up to 3 additional years (i.e., 
5th postoperative year). A physical examination and laboratory 
testing, including serum CEA levels, were performed at each visit. 
Imaging screens, including an abdominopelvic computed tomog-
raphy (CT) scan, were performed every 6 months; chest CT was 
performed annually. Nonroutine magnetic resonance imaging 
and positron emission tomography-CT were performed at the 
clinician’s discretion. Endoscopic examinations were performed 
within the first postoperative year and then every 3–4 years ac-
cording to the findings. 
Statistical analysis
Categorical data are presented as frequencies or percentages. 
Continuous data are presented as means with standard deviations 
or medians with ranges. Intergroup differences were analyzed us-
ing the chi-square test, Student t-test, and Mann-Whitney U-test. 
The Kaplan-Meier method was used to analyze survival, and the 
resulting curves were compared using the log-rank test. Cox pro-
portional hazard model was used for the univariate and the mul-
tivariate analyses of the prognostic factors. All variables that were 
significant in the univariate analysis were included in the multi-
variate analysis. A P-value < 0.05 was considered significant, and 
confidence intervals (CIs) were calculated at the 95th percentile 
level. IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA) 
was used for the statistical analysis.
RESULTS
Grouping of patients according to PNI differences
A total of 261 consecutive patients were enrolled in this study. Pa-
tients were divided into the following 3 groups according to dPNI 
values (defined above): dPNI-low, dPNI < 5; dPNI-moderate, 
dPNI of 5–10; and dPNI-high, dPNI > 10 (Fig. 2).
Clinicopathologic characteristics and short-term outcomes
The clinicopathologic characteristics and short-term outcomes of 
the three groups were evaluated (Table 1). The median follow-up 
duration was 48 months (range, 1–91 months). Approximately 
88% of the patients received adjuvant chemotherapy. Except for 
preoperative BMI, no statistically significant intergroup differ-
ences were observed in terms of patient characteristics or tumor 
and operative parameters. Additionally, no significant differences 
were observed in short-term operative outcomes, including the 
incidence of high-grade (Clavien-Dindo grade III–IV) periopera-
tive complications and 30-day mortality rate. The proportion of 
low rectal cancers (tumor location within 5 cm from the anal 
verge) tended to be higher in the dPNI-high group, but this dif-
ference was not statistically significant.
Long-term oncologic outcomes
Kaplan-Meier survival curves demonstrated that both the disease-
free survival (DFS) and the cancer-specific survival (CSS) out-
comes were worse in the dPNI-high group relative to the other 
groups (DFS: P < 0.001, Fig. 1; CSS: P = 0.02, Figs. 3, 4). The uni-
variate and the multivariate analyses of the DFS demonstrated 
that the ypT stage, ypN stage, and dPNI were independent pre-
dictors for DFS (Table 2). Furthermore, histology, ypT stage, and 
dPNI were identified as significant prognostic factors for CSS 
(Table 3).
DISCUSSION
Since its initial introduction by Onodera et al. in 1986 [19], the 
PNI has been identified as an independent prognostic factor in 
various types of cancer [11-17, 19]. Furthermore, in recent studies 
of patients with colorectal cancer, the PNI was found to be associ-
ated not only with surgical morbidity, but also with long-term on-
cologic outcomes [14-16]. To the best of our knowledge, however, 
no studies have evaluated the prognostic significance of the PNI 
in patients with LARC. Furthermore, this study is the first to in-
troduce the dPNI, a parameter that demonstrates the significance 
of a serial change of the PNI rather than of a single value mea-
sured at a specific time point.
More than half of the enrolled patients were classified into the 
dPNI-low group, and the PNI values of approximately a third of 
the patients in this group actually increased during the study. 
However, long-term oncologic outcomes did not significantly dif-
Difference of PNI < 5
(n =138)
PNI difference-Low
5 ≤ Difference of PNI ≤10 
(n =38)
PNI differenc-Moderate
Difference of PNI
= Pre-CRT PNI – post-CRT PNI
10 < Difference of PNI
(n =40)
PNI difference-High
Fig. 2. Subgroup analysis according to PNI difference values. PNI, 
prognostic nutritional index; CRT, chemoradiation therapy.
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fer between patients in this group with an increased PNI and 
those with a decreased PNI (data not shown). Accordingly, we 
categorized both types of patients into a single dPNI-low category.
In our study, the dPNI was clearly associated with long-term 
oncologic outcomes (DFS, CSS). To date, however, no clear expla-
nation has been given for the correlation between the PNI and 
prognostic significance. Malnutrition is a known risk factor for 
postoperative complications in surgical patients [4, 6, 7]. Some 
Table 1. Patient and tumor characteristics and short-term outcomes (n = 261)    
Variable
dPNI
P-value
<5 (n = 138) 5–10 (n = 83) >10  (n = 40)
Follow-up (mo) 48 (6–88) 48 (3–87) 51 (1–91) 0.780
Age (yr) 59.59 ± 11.50 57.50 ± 10.12 56.72 ± 12.08 0.223
Sex 0.668
   Male 99 (71.7) 55 (66.3) 27 (67.5)
   Female 39 (28.3) 28 (33.7) 13 (32.5)
Pre-CRT BMI (kg/m2) 22.56 ± 2.81 22.45 ± 2.88 23.73 ± 2.93 0.047
Preoperative serum CEA (ng/mL) 0.301
   <5 99 (68.1) 48 (57.8) 26 (65.0)
   ≥5 44 (31.9) 35 (32.2) 14 (35.0)
Differentiation 0.217
   Well + moderate 123 (89.1) 75 (90.4) 32 (80.0)
   Poor + mucinous 15 (10.9) 8 (9.6) 8 (20.0)
Distance from AV (cm) 0.070
   Low (AV < 5) 67 (48.6) 51 (61.4) 26 (65.0)
   Mid/upper (AV ≥ 5) 71 (51.4) 32 (38.6) 14 (35.0)
ASA physical status (%) 0.870
   <III 135 80 39
   ≥III 3 3 1
ypT stage 0.796
   0/1/2 56 (40.6) 37 (44.6) 18 (45.0)
   3/4 82 (59.4) 46 (55.4) 22 (55.0)
ypN stage 0.152
   0 103 (74.6) 53 (63.9) 31 (77.5)
   1/2 35 (25.4) 30 (36.1) 9 (22.5)
Adjuvant therapy 0.744
   Yes 120 (87.0) 75 (90.4) 35 (87.5)
   No 18 (13.0) 8 (9.6) 5 (12.5)
Operation type 0.202
   Open 63 (45.7) 45 (54.2) 60 (60.0)
   MIS 75 (54.3) 38 (45.8) 40 (40.0)
Conversion rate (%) 4 (2.9) 3 (3.6) 0 (0.0) 0.765
Complication (Clavien-Dindo classification) 0.480
   <III 127 (92.0) 77 (92.8) 39 (97.5)
   ≥III 11 (8.0) 6 (7.2) 1 (2.5)
30-Day mortality (%) 0 0 1 NS
Values are presented as median (range), mean ± standard deviaion, or number (%).    
dPNI, prognostic nutritional index difference; CRT, chemoradiation therapy; BMI, body mass index; CEA, carcinoembryonic antigen; AV, anal verge; ASA, American Society 
of Anesthesiologists; MIS, minimal invasive surgery (laparoscopic or robotic); NS, not significant.    
dPNI was calculated as follows: pre-CRT PNI – post-CRT PNI.    
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studies of patients with colorectal cancer have shown that malnu-
trition is associated with a significant risk of wound complications 
and anastomosis site leakage [3, 5]. Poor short-term postoperative 
outcomes might lead to inferior long-term oncologic outcomes 
[21]. However, the postoperative complication rates, including the 
overall and the high-grade complication rates, did not differ sig-
nificantly among the 3 groups in our study.
Previous studies have shown a close correlation of inflammation 
with cancer progression [8]. In colorectal cancer, inflammatory 
markers such as the C-reactive protein level, neutrophil-to-lym-
phocyte ratio (NLR), Glasgow prognostic score (GPS), and modi-
fied GPS (mGPS) have been reported as prognostic markers [22-
24]. Notably, the serum albumin concentration reflects not only a 
patient’s nutritional status, but also chronic inflammation. In ad-
Fig. 3. Kaplan-Meier estimates and log-rank analyses of disease-free 
survival. PNI, prognostic nutritional index.
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Fig. 4. Kaplan-Meier estimates and log-rank analyses of cancer-spe-
cific survival. PNI, prognostic nutritional index.
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Table 2. Univariate and multivariate analyses of predictive factors for disease-free survival    
Factor
Univariate analysis Multivariate analysis
P-value HR 95% CI P-value
Age (<60 yr vs. ≥ 60 yr) 0.833 1.312 0.836–2.059 0.237
Sex (male vs. female) 0.979 0.861 0.528–1.404 0.548
BMI (<18.5 kg/m2 vs. ≥18.5 kg/m2) 0.554 1.402 0.600–3.280 0.435
Histology (WD/MD vs. PD/mucinous) 0.007 1.583 0.871–2.877 0.132
ypT stage (0/1/2 vs. 3/4) 0.002 1.673 1.004–2.787 0.048
ypN stage (0 vs. 1/2) <0.001 2.378 1.494–3.786 <0.001
PNI  (<5) <0.001 0.002
   vs. 5–10 1.705 1.027–2.831 0.039
   vs. >10  2.792 1.577–4.942 <0.001
Complication (Dindo < III vs. ≥ III) 0.490 0.786 0.282–2.191 0.645
ASA score (I/II vs. III/IV) 0.332 1.420 0.442–4.559 0.556
AV distance (LOW vs. MID/UPPER) 0.229 0.672 0.424–1.067 0.092
CEA (<5 ng/mL vs. ≥5 ng/mL) 0.475 0.871 0.540–1.403 0.569
HR, hazard ratio; CI, confidence interval; BMI, body mass index; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, prognostic nutritional 
index; Dindo, Clavien-Dindo classification grade; ASA, American Society of Anesthesiologists; AV, anal verge; LOW, low rectal cancer, AV < 5 cm; MID/UPPER, middle/up-
per rectal cancer, AV ≥ 5 cm; CEA, carcinoembryonic antigen.    
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Table 3. Univariate and multivariate analyses of prognostic factors for cancer-specific survival    
Factor
Univariate analysis Multivariate analysis
P-value HR 95% CI P-value
Age (<60 yr vs. ≥ 60 yr) 0.307 1.679 0.906–3.109 0.099
Sex (male vs. female) 0.674 0.998 0.501–1.987 0.996
BMI (<18.5 kg/m2 vs. ≥18.5 kg/m2) 0.065 2.485 0.969–6.371 0.058
Histology (WD/MD vs. PD/mucinous) <0.001 3.189 1.622–6.269 0.001
ypT stage (0/1/2 vs. 3/4) 0.003 2.395 1.169–4.904 0.017
ypN stage (0 vs. 1/2) 0.029 1.337 0.702–2.549 0.377
PNI (<5) 0.02 0.036
   vs. 5–10 2.469 1.225–4.978 0.012
   vs. >10  2.020 0.883–4.620 0.096
Complication (Dindo < III vs. ≥ III) 0.773 1.631 0.490–5.433 0.426
ASA score (I/II vs. III/IV) 0.301 1.211 0.266–5.513 0.804
AV distance (LOW vs. MID/UPPER) 0.866 0.950 0.500–1.804 0.875
CEA (<5 ng/mL vs. ≥5 ng/mL) 0.498 0.901 0.469–1.731 0.754
HR, hazard ratio; CI, confidence interval; BMI, body mass index; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, prognostic nutritional 
index; Dindo, Clavien-Dindo classification grade; ASA, American Society of Anesthesiologists; AV, anal verge; LOW, low rectal cancer, AV < 5 cm; MID/UPPER, middle/up-
per rectal cancer, AV ≥ 5 cm; CEA, carcinoembryonic antigen.    
dition, the serum lymphocyte count has been identified as an ob-
jective parameter of inflammation. Although the PNI was first in-
troduced to reflect the nutritional status of a cancer patient, the 
prognostic significance of this index can be attributed to its con-
nection with the systemic inflammatory response. 
Based on the findings of our study, patients’ long-term outcomes 
might be enhanced by correcting their immunonutritional status 
during pCRT. Efforts to improve the outcomes of malnourished 
cancer patients by providing perioperative immunonutritional 
support are ongoing [8]. However, previous studies have included 
some limitations. Most studies included inhomogeneous patients 
with GI cancers of different origins; thus, the results were some-
what difficult to interpret [4, 7, 8]. Optimal timing of the immu-
nonutritional intervention may be important. Generally, preoper-
ative immunonutritional intervention is thought to be beneficial 
for patients undergoing GI surgery [25]. However, no available 
studies have discussed when to initiate and for how long to main-
tain an immunonutritional intervention for patients receiving 
pCRT for the treatment of rectal cancer. In the current study, we 
did not observe a significant intergroup difference with regard to 
tumor responses after pCRT or postoperative complications. Ac-
cordingly, such patients might not require immunonutritional in-
tervention before pCRT initiation. The results of our study will 
lead to the design of a further prospective study. An enteral im-
munonutritional formula or parental nutritional formula could 
be provided upon admission to every patient undergoing pCRT, 
and the PNI or other scales, such as NRS-2002, could be used to 
assess improvements in the immunonutritional status. Validation 
of this enhancement of long-term oncologic outcomes in a pro-
spective study could lead to new treatment options, of which pre-
operative immunonutritional support would be the treatment of 
choice. 
The retrospective and single-center design of this study has 
some potential drawbacks. A risk exists for potential bias in pa-
tient selection and potential flaws in the accuracy of the docu-
mented medical records. Furthermore, potential confounding 
factors, such as albumin replacement therapy or infection, which 
could affect the serum albumin level and lymphocyte count, were 
not assessed. An additional weakness of this study is the small 
number of cases.
In patients with LARC, the dPNI during preoperative concur-
rent CRT is predictive of long-term outcomes. Our data suggest 
that correcting the patient’s immunonutritional status during 
concurrent CRT could enhance oncologic outcomes. Such results 
warrant further investigation in the form of a prospective study.
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